Analysts' ratings for Gilead Sciences GILD over the last quarter vary from bullish to bearish, as provided by 22 analysts. The following table encapsulates their recent ratings, offering a glimpse ...

The most recent trading session ended with Gilead Sciences (GILD) standing at $93.85, reflecting a -1.57% shift from the previouse trading day's closing. This move lagged the S&P 500's daily gain ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance ...

Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target remains the same with $95.00. Tyler Van Buren’s ...

Investors with a lot of money to spend have taken a bullish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the trades showed up on publicly ...

Bernstein analyst Courtney Breen maintained a Buy rating on Gilead Sciences (GILD – Research Report) yesterday and set a price target of $105.00. The company’s shares closed yesterday at $96.95.

TEANECK, N.J. - Cognizant Technology Solutions (NASDAQ:CTSH) Corporation (NASDAQ: CTSH) has announced the expansion of its partnership with biopharmaceutical company Gilead Sciences (NASDAQ ...

TEANECK (dpa-AFX) - Cognizant (CTSH) Thursday announced that it has expanded its long-standing collaboration with Gilead Sciences (GILD) to enhance cost efficiency and productivity. The ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

View Gilead Sciences, Inc. (GILD) current and estimated P/E ratio data provided by Seeking Alpha.